Comparative Pharmacology
Head-to-head clinical analysis: AROMASIN versus FEMARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AROMASIN versus FEMARA.
AROMASIN vs FEMARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible steroidal aromatase inhibitor that binds to the aromatase enzyme, leading to its permanent inactivation via covalent modification. This reduces estrogen biosynthesis (primarily in peripheral tissues) by inhibiting conversion of androgens to estrogens.
Aromatase inhibitor; inhibits the conversion of androgens to estrogens by competitively binding to the aromatase enzyme, thereby reducing estrogen levels in peripheral tissues and tumors.
25 mg orally once daily after a meal
2.5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) for exemestane, supporting once-daily dosing. Steady state achieved within 7 days.
The terminal elimination half-life of letrozole is approximately 2 days (range 24–48 hours). Steady-state concentrations are achieved within 2–6 weeks of daily dosing. The long half-life supports once-daily dosing.
Primarily hepatic metabolism via CYP3A4 and aldoketoreductases, with 60-70% of metabolites excreted renally and 30-40% via feces. Less than 1% excreted unchanged in urine.
Letrozole is extensively metabolized in the liver, primarily to an inactive carbinol metabolite. Approximately 90% of an oral dose is excreted in urine, with about 6% as unchanged drug and 84% as metabolites. Fecal excretion accounts for less than 10%.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor